Industry News

• Bayer increases sales and earnings in the second quarter  The Bayer Group once again achieved gains in sales and earnings in the second quarter of 2010. MaterialScience has left the crisis behind and saw business expand more strongly than expected.
  Bayer July 29, 2010  
• NIH-Funded researchers make progress toward regenerating tissue to replace joints   A team of NIH-funded researchers has successfully regenerated rabbit joints using a cutting edge process to form the joint inside the body. Regenerative in vivo procedures are performed by stimulating previously irreparable organs or tissues to heal themselves.
  National Institutes of Health July 29, 2010  
• Helicos BioSciences announces first evidence of RNA copying mechanisms in human cells  Helicos announced publication demonstrating the detection and quantification of novel small RNA molecules using single-molecule sequencing technology. These data confirm a long-held, unproven hypothesis that mammalian cells are capable of synthesizing RNA by copying RNA molecules directly.
  Helicos BioSciences Corporation July 29, 2010  
• Amgen's second quarter 2010 adjusted earnings per share increased 7 percent to $1.38   Amgen reported adjusted EPS of $1.38 for the second quarter of 2010, an increase of 7 percent compared to $1.29 for the second quarter of 2009. Adjusted net income increased 1 percent to $1,326 million for the second quarter of 2010 versus $1,311 million for the second quarter of 2009.
  Amgen July 29, 2010  
• Cardiac Science announces second quarter financial results  Cardiac Science reported revenue for the second quarter of 2010 was $36.1 million equal to second quarter 2009 revenue, and a net loss of $18.5 million including a charge of $11.0 million associated with an announced plan to replace AEDs used by certain first responders and medical providers.
  Cardiac Science Corporation July 29, 2010  
• Boston Scientific announces approval of new leads for Precision Plus Spinal Cord System  Boston Scientific announced FDA approval of two spinal cord stimulation leads for use with its Precision Plus™ Spinal Cord Stimulator System, the world's first rechargeable SCS device for the management of chronic pain of the trunk and/or limbs.
  Boston Scientific Corporation July 29, 2010  
• UCLA scientists find cell-of-origin for human prostate cancer  UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.
  Jonsson Comprehensive Cancer Center July 29, 2010  
• AstraZeneca announce second quarter and half year results  AstraZeneca reported revenue for the second quarter increased by 1 percent to $8,178 million, and operating profit in the second quarter was unchanged at $3,650 million. Reported EPS in the second quarter increased by 22 percent at CER to $1.46.
  AstraZeneca July 29, 2010  
• Medtronic clinical trial evaluates spinal cord stimulation therapy for heart failure  Medtronic announced the launch of Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure) clinical trial, the industry’s first prospective study evaluating clinical feasibility of spinal cord stimulation to improve symptoms of heart failure.
  Medtronic, Inc. July 29, 2010  
• HHS announces availability of $51 million for states to build competitive health insurance  HHS announced the availability of up to $1 million in grants per state to help states begin work to establish Exchanges and published a request for comment calling for public input as HHS develops standards for the Exchanges.
  U.S. Health and Human Services July 29, 2010  

   (next 10 articles)